Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBITDA (2020 - 2025)

Historic EBITDA for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$13.1 million.

  • Maxcyte's EBITDA fell 80.85% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 1623.01%. This contributed to the annual value of -$51.2 million for FY2024, which is 600.01% down from last year.
  • Maxcyte's EBITDA amounted to -$13.1 million in Q3 2025, which was down 80.85% from -$13.1 million recorded in Q2 2025.
  • Maxcyte's EBITDA's 5-year high stood at -$2.4 million during Q3 2021, with a 5-year trough of -$14.0 million in Q3 2023.
  • Its 5-year average for EBITDA is -$9.5 million, with a median of -$10.9 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 3473.98% in 2022, then crashed by 21684.74% in 2023.
  • Quarter analysis of 5 years shows Maxcyte's EBITDA stood at -$5.0 million in 2021, then plummeted by 36.23% to -$6.8 million in 2022, then fell by 19.93% to -$8.1 million in 2023, then plummeted by 59.35% to -$12.9 million in 2024, then fell by 1.48% to -$13.1 million in 2025.
  • Its last three reported values are -$13.1 million in Q3 2025, -$13.1 million for Q2 2025, and -$12.3 million during Q1 2025.